The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms Abstract #833

Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Aim(s): In the present study, the expression of the CXCR4 was evaluated in a panel of neuroendocrine tumors of the lung, comprising typical carcinoids (TC), atypical carcinoids (AC) and small cell lung cancer (SCLC).
Materials and methods: CXCR4 expression was assessed by means of immunohistochemistry (IHC) using the novel rabbit anti-CXCR4 antibody UMB-2 and by qRT-PCR. The staining was quantified with three different scoring systems. Both IHC and qRT-PCR results were correlated with patient data. Additionally, endogenous CXCR4 expression was assessed in different cancer cell lines by means of immunocytochemistry.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Christiane Anne Reimann

To read results and conclusion, please login ...

Further abstracts you may be interested in

#877 Immunohistochemical and qRT-PCR-Based Evaluation of Somatostatin Receptor 1 to 5 Expression in 92 Patients with Bronchopulmonary Neuroendocrine Neoplasms
Introduction: Little is known about the somatostatin receptor (SSTR) status in bronchopulmonary neuroendocrine neoplasms (BP-NEN), comprising typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancer (SCLC) and large cell neuroendocrine lung carcinomas (LCNEC).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Elisa Specht
#879 The Assessment of Proliferation in BP-NEN Entities Based on the Three Proliferation Markers Ki-67, TOP2A and RacGAP1
Introduction: The extent of cell proliferation as an important component of carcinogenesis can be detected in tumor tissues by means of various factors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Elisa Specht
#1162 Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis
Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Lydia Schmidt
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu